Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pelvic Inflammatory Disease Clear all
Completed No phase listed Observational

The Role of Novel Organisms in Acute Endometritis

NCT01236131
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
no intervention
Other
Lead sponsor
Sharon Hillier
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

NCT00004074
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
Interventions
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated No phase listed Observational

MDR - Longevity IT Oblique and Offset Liners

NCT05980234
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip
Interventions
Total Hip Arthroplasty with Longevity IT Oblique Liners, Total Hip Arthroplasty with Longevity IT Offset Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery

NCT01464840
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections

NCT04163679
View directory record Official record
Conditions
Infection, Obstetric Labor Complications, Endometritis, Cesarean Delivery Affecting Fetus, Wounds Injuries
Interventions
Vaginal Preparation
Procedure
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 64 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

NCT01160640
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Technology Enhanced Community Health Nursing (TECH-N) Study

NCT01640379
View directory record Official record
Conditions
Pelvic Inflammatory Disease (PID)
Interventions
Technology Enhanced Community Health Nursing
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Not applicable Interventional

Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II

NCT03828994
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Tech-PN
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Feasibility and Safety of Single Port Robot in Colorectal Procedures

NCT03700593
View directory record Official record
Conditions
Colon Cancer, Colon Polyp, Rectal Cancer, Diverticulitis, Prolapse, Rectal, Rectal Polyp, Inflammatory Bowel Diseases
Interventions
Single Port Robotic Colorectal Surgery
Device
Lead sponsor
Marks Colorectal Surgical Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine

NCT00858832
View directory record Official record
Conditions
Endometritis
Interventions
Methergine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

LOIS: Long-Term Follow-Up in INSITE/SIFI

NCT02270203
View directory record Official record
Conditions
Degenerative Sacroilitis, Sacroiliac Joint Disruption
Interventions
Pelvic CT at 5 years post-op
Radiation
Lead sponsor
SI-BONE, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
New Haven, Connecticut • Stockbridge, Georgia • Mount Vernon, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnostic Challenges in IC (and Male CPPS)

NCT00672087
View directory record Official record
Conditions
Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Chronic Bacterial Prostatitis, Asymptomatic Inflammatory Prostatitis, Painful Bladder Syndrome, Cystitis, Interstitial
Interventions
Genomic and proteomic biomarker discovery
Genetic
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MOCHI: An RCT of Mindfulness as Treatment for Chronic Pelvic Pain in AD Women

NCT04104542
View directory record Official record
Conditions
Chronic Pelvic Pain, Depression, Inflammation Pelvic
Interventions
Mindfulness based stress reduction, Healthy Lifestyle
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity

NCT00603603
View directory record Official record
Conditions
Infection; Cesarean Section, Surgical Wound Infection, Endometritis
Interventions
80% inhaled oxygen via non-rebreather mask, 30% inhaled oxygen via nasal cannula
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 50 Years · Female only
Enrollment
606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Cleansing Before Cesarean Delivery to Reduce Infection

NCT02495753
View directory record Official record
Conditions
Complications; Cesarean Section
Interventions
Vaginal Cleansing, Abdominal Cleansing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Results available

Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

NCT01640353
View directory record Official record
Conditions
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
Interventions
Not listed
Lead sponsor
SI-BONE, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Huntsville, Alabama • Campbell, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

STRIPES Study: Study To Reduce Infection Post cEsarean Section

NCT02402907
View directory record Official record
Conditions
Chlorhexidine Gluconate Cloths, Infection; Cesarean Section, Infectious Morbidity, Surgical Site Infections, Endometritis
Interventions
2% chlorhexidine gluconate (CHG) cloth, Placebo cloth
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
1,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

NCT01299259
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Text Message Reminders
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
15 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

Prevention of Surgical Site Infection After Cesarean Delivery

NCT02027324
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine-alcohol group, Povidone-Iodine Group
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

NCT01793584
View directory record Official record
Conditions
Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions
Laparoscopic hysterectomy, Abdominal hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

NCT04578015
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn Phase 4 Interventional

Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis

NCT01721616
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin, Cefazolin
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional Results available

Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial

NCT00386477
View directory record Official record
Conditions
Cesarean Section, Endometritis, Surgical Wound Infection
Interventions
Vaginal cleansing before cesarean delivery
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Jul 21, 2026, 2:19 PM EDT